SCHEMBL2178685

SCHEMBL2178685

CC(C)[C@@H](C(=O)O)N1Cc2cc(-c3ccc(NS(=O)(=O)c4ccc(F)c(F)c4)cc3)ccc2C1=O

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PRF1 P14222 4/20 0.48
SDCBP O00560 3/20 0.45
SDC2 P34741 3/20 0.45
LMNA P02545 3/20 0.43
GFER P55789 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPT P10636 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
KIT P10721 1/20 0.39
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
IDH2 P48735 1/20 0.38
DRD2 P14416 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
DRD3 P35462 1/20 0.38
HTR6 P50406 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2180412 1.00 PRF1 (0.48) PRF1SDCBPSDC2LMNAGFER
SCHEMBL2179719 0.93 LMNA (0.41) PRF1SDCBPSDC2LMNAGFER
SCHEMBL2179136 0.93 LMNA (0.41) PRF1SDCBPSDC2LMNAGFER
SCHEMBL2179727 0.87 MMP13 (0.47) PRF1SDCBPSDC2LMNAKIT
SCHEMBL2180290 0.87 PGR (0.51) PRF1SDCBPSDC2LMNAMAPT
SCHEMBL2177958 0.87 MMP13 (0.47) PRF1SDCBPSDC2LMNAKIT
SCHEMBL2178519 0.87 PGR (0.51) PRF1SDCBPSDC2LMNAMAPT
SCHEMBL2179895 0.86 PRF1 (0.49) PRF1SDCBPSDC2LMNASMN1; SMN2
SCHEMBL2179842 0.86 PRF1 (0.49) PRF1SDCBPSDC2LMNASMN1; SMN2
SCHEMBL2179996 0.86 LMNA (0.51) PRF1SDCBPSDC2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT PRF1 4578/4885SDCBP 2373/4885SDC2 3855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.